CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (Unaudited) - USD ($) shares in Millions, $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Revenues:
Revenues	$ 2,294.0	$ 1,743.7	$ 6,074.2	$ 4,694.1
Expenses:
Research and development	684.6	526.0	1,990.5	1,897.6
Selling, general, and administrative	326.9	304.4	1,042.5	890.1
Other operating (income) expense, net	(44.6)	(50.7)	(135.2)	(171.1)
Total operating expenses	1,240.9	1,005.2	3,664.6	3,160.0
Income from operations	1,053.1	738.5	2,409.6	1,534.1
Other income (expense):
Other (expense) income, net	(28.5)	37.8	218.3	28.7
Interest expense	(26.3)	(7.8)	(42.1)	(23.5)
Total other income (expense)	(54.8)	30.0	176.2	5.2
Income before income taxes	998.3	768.5	2,585.8	1,539.3
Income tax expense	156.2	98.9	221.8	215.5
Net income	$ 842.1	$ 669.6	$ 2,364.0	$ 1,323.8
Net income per share - basic (in dollars per share)	$ 7.98	$ 6.12	$ 21.83	$ 12.12
Net income per share - diluted (in dollars per share)	$ 7.39	$ 5.86	$ 20.36	$ 11.54
Weighted average shares outstanding - basic (in shares)	105.5	109.4	108.3	109.2
Weighted average shares outstanding - diluted (in shares)	113.9	114.2	116.1	114.7
Statements of Comprehensive Income
Net income	$ 842.1	$ 669.6	$ 2,364.0	$ 1,323.8
Other comprehensive income (loss), net of tax:
Unrealized (loss) gain on debt securities	(4.9)	1.0	10.9	31.5
Unrealized gain (loss) on cash flow hedges	0.2	(0.3)	(1.2)	(2.7)
Comprehensive income	837.4	670.3	2,373.7	1,352.6
Product
Revenues:
Revenues	1,482.2	1,238.3	3,945.8	3,548.0
Expenses:
Cost of goods sold	131.0	115.9	312.3	253.8
Collaboration and contract manufacturing
Expenses:
Cost of goods sold	143.0	109.6	454.5	289.6
Sanofi | Product and service, other
Revenues:
Revenues	353.3	175.0	869.3	232.8
Bayer | Product and service, other
Revenues:
Revenues	299.9	293.6	825.5	834.8
Other | Product and service, other
Revenues:
Revenues	$ 158.6	$ 36.8	$ 433.6	$ 78.5